Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from InhaleRx Limited ( (AU:IRX) ).
InhaleRx Limited, an Australian clinical-stage drug developer, specialises in rapid-onset, inhaled therapies for indications in pain management and mental health. The company is advancing a pipeline led by IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder, and SRX-25 for treatment-resistant depression, underpinned by a sizeable funding facility and a strategy focused on cost-effective U.S. regulatory routes.
The company announced that its CEO, Darryl Davies, and medical advisor, Dr. Sud Agarwal, will host an investor webinar on 12 February 2026 to outline extensive clinical development plans for the year ahead. The briefing, which will be accessible live and via replay, is expected to provide investors and other stakeholders with greater visibility on InhaleRx’s development timelines and may clarify how its funding and regulatory strategy could accelerate market entry for its key programs.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company focused on rapid-onset, inhaled therapies targeting unmet medical needs in pain management and mental health. Its lead programs include IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder, and SRX-25 for treatment-resistant depression, supported by a funding facility of up to $52.3 million to pursue U.S. FDA approval via streamlined regulatory pathways.
Average Trading Volume: 268,655
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.91M
Learn more about IRX stock on TipRanks’ Stock Analysis page.